News RSS

MYCAB NEWS

MYCAB

Flight Centre boosts ground transport offering for Corporate clients with MYCAB and Amadeus.

Read more »

WideCells has launched WideAcademy

WideCells Group Limited is a worldwide provider of stem cell-based services. Our mission is to provide individuals and families access to affordable stem cell treatment globally.

WideCells has launched the WideAcademy Podcast

The Wideacademy Podcast is a new monthly series presented by Brhmie Balaram, bringing you the latest news, developments and information from the world of stem cell research and tech. 

Listen their podcast here:

https://soundcloud.com/user-238415383

 

Read more »

UPDATE FROM MYTOWN

MYTOWN

Dear Members and Shareholders,

A quick update to let you know that the new platform will be live on the 15th August and the new app will follow 2 weeks later! Sorry for the delay but it will be worth it.

We have now partnered with Google, Ticketmaster, Groupon, Zoopla, Viator, Zumato, Booking.com, Cimenas2Go, Ebay, Exchange and Mart and many more!

Dominic Brookman | MyTown

Read more »

NEW MYCAB WEBSITE

MYCAB

PRESSRELEASE JULY 2018

We are delighted to announce a new chapter in the online experience for MYCAB customers and partners – as we continue to evolve with a brand new MYCAB International website alongside a major update to mycabtravel.com

MYCAB’s clear growth strategy is provide world-class ground transfer services that integrate seamlessly with the managed travel industry eco-system – working with the brightest and many of the biggest TMCs, Travel Agencies and major GDS platforms.

The new www.mycabinternational.com provides a comprehensive overview of MYCAB’s products and services, features and benefits most relevant to customers and partners alongside information about the business and leadership team. The site is also is a new hub for the latest news and blog posts, as well as ways for customers and passengers to get in touch

The new website is now fully integrated with the legacy www.mycabtravel.com site, which remains as a booking hub for direct customers. In the coming months we will integrate these sites into one, with a new streamlined booking process. In addition new region specific versions will go live, such as in the Middle East, Scandinavia and North America and the site will continue to evolve in content and functionality. We welcome all feedback – please email us at support@mycabtravel.com.

James Raffo | CMO MYCAB

Read more »

STOCKHOLM IT VENTURES ACQUISITION OF FANTRAC GLOBAL FAILS TO COMPLETE

Stockholm IT Ventures

 

STOCKHOLM IT VENTURES ACQUISITION OF FANTRAC GLOBAL FAILS TO COMPLETE

 

Luxembourg, 4th July 2018, the below announcement was made on the Stockholm IT Ventures website earlier today stating that the acquisition of Fantrac failed to complete. We have since been in touch with both Fantrac directors and SITV board.

The Directors of Fantrac maintain that the acquisition did complete and accordingly they have instructed lawyers in Sweden to pursue the matter. Mr Lochner the CEO of Fantrac stated that every effort was being made to try and resolve this matter.

The Board of SITV were not available for comment

Our view is that this will probably end up being a legal matter and the outcome is unpredictable. We will continue to work in the best interest of our members exposed to this situation.

 

July 4, 2018 in Press Release

STOCKHOLM, SWEDEN (4th July, 2018) – Stockholm IT Ventures AB (Frankfurt Stock Exchange: SVAB), a Swedish technology company specialising in clean and efficient low-cost energy cryptocurrency mining, today announced that following the appointment of a new Board of Directors on 1 February 2018, the Board conducted a root and branch review of all material contracts that the Company (SITV) had entered into during the previous two years. This process was put in place to ensure that the business had acted in the best interests of shareholders and that all legal obligations had been properly recorded. The Company appointed legal advisers KLA Legal, based in Stockholm, to assist in the review.

The Board has now received a legal overview from KLA specifically on the proposed acquisition of Fantrac Global. The legal position is that the transaction failed to complete at the time as conditions precedent were not met by the end date of 21 March 2017.  Stockholm IT Ventures did not issue any shares in relation to this transaction and therefore existing shareholders are not affected.

“Our main objective is and will always to serve the best purposes of our business and value to our shareholders,” said Anthony Norman, CEO, Stockholm IT Ventures. “As we forge ahead with our new team fulfilling on our vision for a new world crypto and digital financial services market landscape, we will continue to address business alignments that do not serve our greater purpose.”

The Company has tried to come to new terms with Fantrac in the intervening period, which has not resulted in an agreement and, therefore, Stockholm IT Ventures has now formally informed Fantrac that the transaction has failed to complete. The Board has since terminated all further discussions with Fantrac.

Read more »

WCG – Result of General Meeting

Widecells Group PLC

 

PRESSRELEASE • WCG • 28 June 2018

 

WIDECELLS GROUP – Result of General Meeting

WideCells Group PLC, the healthcare services company focused on providing stem cell services and ground-breaking insurance for stem cell treatment, is pleased to announce that following the Group's General Meeting held earlier today, all resolutions were duly passed.   As a result, the Placing (see announcements dated 10 May 2018, 5 June 2018, 11 June 2018 and 12 June 2018 for further information) is now unconditional, save for Admission.

An application has been made for admission of a total of 68,698,355 new ordinary shares of £0.0025 (Ordinary Shares) each, (being 67,865,022 Placing Shares and 833,333 Fee Shares, as set out in the Company's prospectus dated 12 June 2018) on the Official List of the FCA and to trading on the London Stock Exchange's main market for listed securities (Admission).  Admission is expected to take place at 8.00 am on 29 June 2018.

Following Admission, the Company's total issued share capital will consist of 133,519,365 Ordinary Shares.  As each ordinary share carries one vote the total number of voting rights attached to the ordinary shares in the Company is 133,519,365.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in ordinary shares in the Company in accordance with the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

WideCells Group PLC

WideCells Group PLC is building an integrated stem cell services company, focused on making stem cell treatments accessible and affordable. This is achieved through three divisions:

  • CellPlan: the world's first stem cell healthcare insurance plan with financial cover for medical treatment, travel and accommodation expenses and concierge service to manage the treatment process.
  • WideCells: The Institute of Stem Cell Technology has been established and is based in the University of Manchester Innovation Centre to provide stem cell storage services and focus on stem cell research and regenerative medicine. Its international cryogenics division specialises in stem cell storage, with the Group currently offering umbilical cord blood and tissue storage services to clients in the UK and Europe under the brand name BabyCells.
  • WideAcademy: an education and training division to promote awareness of the benefits of stem cell storage across the global general practice community.

The Group has built an experienced senior management team that has been integral to the development of its growth and business to date.

Stem Cell Fast Facts:

  • Cord blood (which is taken from the umbilical cord) provides the most effective source of stem cells for families due to it being simple, safe and painless to collect relative to other sources of stem cells such as bone marrow - WideCells will focus on promoting the collection and storage of cord blood.
  • Since 2005, there has been a 300% increase in the number of illnesses that can be treated using stem cells.
  • 82 illnesses can currently be treated using stem cell procedures.
  • Despite initial storage often costing no more than a few £thousand, actual treatment can cost in the £hundreds of thousands

END

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). On publication of this announcement, this inside information is now considered to be in the public domain.

 

Read more »
I hate snow